Survey

With the recent announcement of Medco's acquisition by Express Scripts, potentially bringing 2 of the nation's largest PBMs together, what do you see as the most significant implications of such consolidation for the industry?

a) Enhanced competition within the industry, inevitably translating to even lower drug costs for PBM payer clients.

b) Unfair advantages for Express Scripts based upon its size, thus reducing competition and potentially increasing long-term costs for payers.

c) Increased pressures on retail pharmacies forcing more pharmacies out of business.

d) Increased quality of PBM clinical, analytic and administrative services across the industry, as other PBMs strive to stay competitive.

e) Minimal, if any, impact.

Digital Edition

Long-term use of nonaspirin NSAIDs may increase RCC risk

To confirm your e-newsletter subscription, click here.

To ensure future delivery of email newsletters from Formulary, please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff

CONTINUING PHARMACY EDUCATION

Drug Topics and The University of Connecticut School of Pharmacy launch the next generation of learning for pharmacists

Anti-nausea drug ondansetron may lead to fatal arrhythmias: FDA

FDA approves first biologic treatment for children with ulcerative colitis

FDA has approved infliximab (Remicade, Janssen Biotech) for the treatment of moderately to severely active ulcerative colitis in pediatric patients older than 6 years who have had an inadequate response to conventional therapy. Read full article.

FDA panel recommends labels on bisphosphonates clarify length of use

The labeling for bisphosphonates needs to be more specific with regard to how long the drugs should be used for the treatment of osteoporosis, an advisory panel to FDA recently recommended. Read full article.

Changes needed to pharma marketing practices

Industry-wide changes in the way pharmaceutical companies conduct marketing activities are needed, according to a recent study published September 12, 2011, in Archives of Internal Medicine. Read full article.

Intranasal insulin may benefit patients with aMCI and AD

Intranasal insulin may have a therapeutic benefit for adults with amnestic mild cognitive impairment (aMCI) or Alzheimer’s disease (AD), according to the results of a pilot study reported online September 12, 2011, in the Archives of Neurology. Read full article.

NSAID use low but not rare among patients with CKD

Healthcare providers should be aware of the use of nonsteroidal anti-inflamatory drugs (NSAIDs) among patients with chronic kidney disease (CKD) and may need to more clearly communicate risks and benefits, according to the results of a study reported in the September/October issue of Annals of Family Medicine. Read full article.